OBJECTIVE: Previous studies have evaluated the correlation between rheumatoid arthritis (RA) risk and pregnancy history, with conflicting results. Fetal cells acquired during pregnancy provide a potential explanation for modulation of RA risk by pregnancy. The present study was undertaken to examine the effect of parity on RA risk. METHODS: We examined parity and RA risk using results from a population-based prospective study in Seattle, Washington and the surrounding area and compared women who were recently diagnosed as having RA (n = 310) with controls (n = 1,418). We also evaluated the distribution of parity in cases according to HLA genotype. RESULTS: We found a significant reduction of RA risk associated with parity (relative risk [RR] 0.61 [95% confidence interval 0.43-0.86], P = 0.005). RA risk reduction in parous women was strongest among those who were younger. Most striking was that RA risk reduction correlated with the time that had elapsed since the last time a woman had given birth. RA risk was lowest among women whose last birth occurred 1-5 years previously (RR 0.29), with risk reduction lessening progressively as the time since the last birth increased (for those 5-15 years since last birth, RR 0.51; for those >15 years, RR 0.76), compared with nulliparous women (P for trend = 0.007). No correlation was observed between RA risk and either age at the time a woman first gave birth or a woman's total number of births. Among cases with the highest genetic risk of RA (i.e., those with 2 copies of RA-associated HLA alleles), a significant underrepresentation of parous women versus nulliparous women was observed (P = 0.02). CONCLUSION: In the present study, there was a significantly lower risk of RA in parous women that was strongly correlated with the time elapsed since a woman had last given birth. While the explanation for our findings is not known, HLA-disparate fetal microchimerism can persist many years after a birth and could confer temporary protection against RA.
OBJECTIVE: Previous studies have evaluated the correlation between rheumatoid arthritis (RA) risk and pregnancy history, with conflicting results. Fetal cells acquired during pregnancy provide a potential explanation for modulation of RA risk by pregnancy. The present study was undertaken to examine the effect of parity on RA risk. METHODS: We examined parity and RA risk using results from a population-based prospective study in Seattle, Washington and the surrounding area and compared women who were recently diagnosed as having RA (n = 310) with controls (n = 1,418). We also evaluated the distribution of parity in cases according to HLA genotype. RESULTS: We found a significant reduction of RA risk associated with parity (relative risk [RR] 0.61 [95% confidence interval 0.43-0.86], P = 0.005). RA risk reduction in parous women was strongest among those who were younger. Most striking was that RA risk reduction correlated with the time that had elapsed since the last time a woman had given birth. RA risk was lowest among women whose last birth occurred 1-5 years previously (RR 0.29), with risk reduction lessening progressively as the time since the last birth increased (for those 5-15 years since last birth, RR 0.51; for those >15 years, RR 0.76), compared with nulliparous women (P for trend = 0.007). No correlation was observed between RA risk and either age at the time a woman first gave birth or a woman's total number of births. Among cases with the highest genetic risk of RA (i.e., those with 2 copies of RA-associated HLA alleles), a significant underrepresentation of parous women versus nulliparous women was observed (P = 0.02). CONCLUSION: In the present study, there was a significantly lower risk of RA in parous women that was strongly correlated with the time elapsed since a woman had last given birth. While the explanation for our findings is not known, HLA-disparate fetal microchimerism can persist many years after a birth and could confer temporary protection against RA.
Authors: Anouk L Feitsma; Jane Worthington; Annette H M van der Helm-van Mil; Darren Plant; Wendy Thomson; Jennie Ursum; Dirkjan van Schaardenburg; Irene E van der Horst-Bruinsma; Jon J van Rood; Tom W J Huizinga; René E M Toes; René R P de Vries Journal: Proc Natl Acad Sci U S A Date: 2007-12-06 Impact factor: 11.205
Authors: J M Rak; L Maestroni; N Balandraud; S Guis; H Boudinet; M C Guzian; Z Yan; D Azzouz; I Auger; C Roudier; M Martin; R Didelot; J Roudier; N C Lambert Journal: Arthritis Rheum Date: 2009-01
Authors: S E Peterson; J L Nelson; K A Guthrie; V K Gadi; T M Aydelotte; D J Oyer; S W Prager; H S Gammill Journal: Hum Reprod Date: 2012-06-29 Impact factor: 6.918
Authors: Hilary S Gammill; Katherine A Guthrie; Tessa M Aydelotte; Kristina M Adams Waldorf; J Lee Nelson Journal: Blood Date: 2010-07-13 Impact factor: 22.113
Authors: William F N Chan; Christopher J Atkins; David Naysmith; Nicholas van der Westhuizen; Janet Woo; J Lee Nelson Journal: Arthritis Rheum Date: 2012-02
Authors: Mary A M Rogers; Deborah A Levine; Neil Blumberg; Gwenith G Fisher; Mohammed Kabeto; Kenneth M Langa Journal: J Autoimmun Date: 2011-08-30 Impact factor: 7.094
Authors: Lynn D Haynes; Walker A Julliard; Joshua D Mezrich; Glen Leverson; Keith C Meyer; William J Burlingham Journal: Transplantation Date: 2018-07 Impact factor: 4.939
Authors: Kevin D Deane; M Kristen Demoruelle; Lindsay B Kelmenson; Kristine A Kuhn; Jill M Norris; V Michael Holers Journal: Best Pract Res Clin Rheumatol Date: 2017-09-18 Impact factor: 4.098
Authors: Kimberly K Ma; J Lee Nelson; Katherine A Guthrie; Carin E Dugowson; Hilary S Gammill Journal: Arthritis Rheumatol Date: 2014-03 Impact factor: 10.995